Your browser doesn't support javascript.
Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic.
Price, Elizabeth; MacPhie, Elizabeth; Kay, Lesley; Lanyon, Peter; Griffiths, Bridget; Holroyd, Christopher; Abhishek, Abhishek; Youngstein, Taryn; Bailey, Kathryn; Clinch, Jacqui; Shaikh, Muddassir; Rivett, Ali.
  • Price E; Great Western Hospital, Swindon, UK and president, British Society for Rheumatology, London, UK elizabeth.price5@nhs.net.
  • MacPhie E; Lancashire and South Cumbria NHS Foundation Trust, Preston, UK and chair of the Clinical Affairs Committee, British Society for Rheumatology, London, UK.
  • Kay L; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK and joint national clinical lead for rheumatology, NHS England and Improvement, London, UK.
  • Lanyon P; Nottingham University Hospitals NHS Trust, Nottingham, UK and national clinical co-lead for rheumatology, NHS Improvement, London, UK.
  • Griffiths B; Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK and chair of the Specialised Rheumatology Clinical Reference Group, NHS England, London, UK.
  • Holroyd C; University Hospital Southampton, Southampton, UK.
  • Abhishek A; The University of Nottingham, Nottingham, UK and Nottingham Biomedical Research Centre, Nottingham, UK.
  • Youngstein T; Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Bailey K; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Clinch J; Bristol Royal Hospital for Children, Bristol, UK and medical lead, Bath Centre for Pain Services, Bath, UK.
  • Shaikh M; James Cook University Hospital, Middlesbrough, UK.
  • Rivett A; British Society for Rheumatology, London, UK.
Clin Med (Lond) ; 2020 May 05.
Article in English | MEDLINE | ID: covidwho-2302050
ABSTRACT
Rheumatology teams care for patients with diverse, systemic autoimmune diseases who are often immunosuppressed and at high risk of infections. The current COVID-19 pandemic has presented particular challenges in caring for and managing this patient group. The office of the chief medical officer (CMO) for England contacted the rheumatology community to provide expert advice on the identification of extremely vulnerable patients at very high risk during the COVID-19 pandemic who should be 'shielded'. This involves the patients being asked to strictly self-isolate for at least 12 weeks with additional funded support provided for them to remain at home. A group of rheumatologists (the authors) have devised a pragmatic guide to identifying the very highest risk group using a rapidly developed scoring system which went live simultaneous with the Government announcement on shielding and was cascaded to all rheumatologists working in England.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2020 Document Type: Article Affiliation country: Clinmed.2020-0149

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2020 Document Type: Article Affiliation country: Clinmed.2020-0149